Eaton Vance Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Eaton Vance Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-700	Closed	–	–	2927
2021 Q3	$0	Sell	700 -550	-44%	-$6.43K	﹤0.01%	2880
2021 Q2	$12K	Buy	+1,250	New	+$11.8K	﹤0.01%	2522

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Eaton Vance Management's TRIL Position: Q4 2021 in Review

Eaton Vance Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 700 shares.

Eaton Vance Management first reported a position in TRIL in Q2 2021 and held it in 2 quarters. The position peaked at $12K in Q2 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Eaton Vance Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Eaton Vance Management sold 700 Trillium Therapeutics Inc. shares in Q4 2021.
Eaton Vance Management first reported a position in Trillium Therapeutics Inc. in Q2 2021 and held it in 2 quarters.
Eaton Vance Management's Trillium Therapeutics Inc. position peaked at $12K in Q2 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Eaton Vance Management's 13F filing for Q4 2021, filed 14 Feb 2022.